Pharmaceutical News and Articles

Clinical Trial Results

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.


RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, presented updates on the development of the company's...
SAN DIEGO, Nov. 6 /PRNewswire/ -- NexBio Inc., in collaboration with scientists at the Centers for Disease Control and Prevention (CDC), St. Louis University, and the University of Hong Kong, announced today the publication of two articles in...
ITCA 650 induces potent reductions of HbA1c and body weight after 4 week treatment; ITCA 650 delivers up to 12 months of exenatide therapy from a single DUROS device HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two...
Oncolytics Biotech® Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting CALGARY, AB, November 6, 2009 - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) (“Oncolytics” or the “Company”)...
-- Palifosfamide prolongs progression-free survival by at least 50% -- NEW YORK--(BUSINESS WIRE)--Nov 6, 2009 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive...
ALISO VIEJO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that results from the week-72 analysis for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in...
Cambridge (United Kingdom), 5 November 2009: New data published today in the journal, Cancer, reveals that three quarters (75%) of patients with indolent B-cell non-Hodgkin’s lymphoma (iNHL), responded to treatment with Bendamustine following a...
Frazer, Pa. – November 5, 2009 – Cephalon, Inc. (Nasdaq: CEPH) today announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with...
Sanofi Pasteur Presents Safety Data on Menactra® Vaccine Given to Infants at Infectious Disease Society Meeting  The two-dose meningococcal quadrivalent conjugate vaccine was generally well-tolerated   Philadelphia, PA – November 2, 2009...
Large study finds subset of women that may need additional therapy HOUSTON , Nov. 2, 2009- Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared...
ROCHESTER, N.Y., Nov. 5 /PRNewswire-USNewswire/ -- A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in...
Phase 3 Results Reinforce Importance of KRAS Status THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in...
AST-120 Also Shown to Reduce Ammonia and Brain Swelling in Rat Model of Cirrhosis BOSTON, Nov. 2 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that AST-120 (spherical carbon adsorbent) was shown to reduce the severity of pruritus...
Complete durable eradication of disease achieved in a significant number of patients with investigational therapy for advanced Stage III and Stage IV melanoma WOBURN, Mass., Nov. 2 /PRNewswire/ -- BioVex Inc, a company developing new generation...
CHICAGO, Nov. 2 /PRNewswire-USNewswire/ -- Short-term hormone therapy given prior to and during radiation treatment to medium-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation...
The Autism Research Institute calls for further investigations into the use of chelation therapy for individuals with autism SAN DIEGO, Nov. 5 /PRNewswire-USNewswire/ -- Two studies published by the Southwest College of Naturopathic Medicine in...
Findings from Pfizer-Sponsored Study Presented as Late-Breaker at American College of Chest Physicians Annual Meeting SAN DIEGO--(BUSINESS WIRE)--Nov 4, 2009 - New study results showed that 42.3 percent of smokers with mild-to-moderate...
– Research Findings Include Rational Design of Mimetic Lipoprotein Particles (MLPs), a Novel Delivery Technology, New Data Regarding Potency of RNAi-Mediated Gene Silencing, and an Update on RNA Activation Research Efforts – CAMBRIDGE,...
LAS VEGAS, Nov. 4 /PRNewswire/ -- New findings presented today show that CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) is the only stimulant medication with data that demonstrate a significant treatment effect on...
LAS VEGAS, Nov. 4, 2009 – New findings presented today show that CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) is the only stimulant medication with data that demonstrate a significant treatment effect on attention at...
More...

Clinical Trial Results Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec

MedNotes
Advertisement

(web9)